patients with emesis gravidarum who take a chewing gum with vitamin C (verum) "ad libitum" several times daily for 2 weeks

patients with emesis gravidarum who take chewing gum without vitamin C (placebo) "ad libitum" several times daily for 2 weeks

patients with emesis gravidarum who do not use chewing gum during the study phase

Hyperemesis Gravidarum

Nausea Gravidarum

Vitamin C Deficiency

Using a chewing gum with 150mg vitamin C (per piece/gum) for 14 days "ad libitum"

Pregnan-C-Gum(R) chewing gum

Using a chewing gum without vitamin C (per piece/gum) for 14 days "ad libitum"

Placebo chewing gum

Medical University of Vienna, Dept. of Obstetrics and Gynecology

Chewing Gum Containing Vitamin-c to Treat Emesis Gravidarum

Chewing Gum Containing Vitamin-c to Treat Emesis Gravidarum: a Randomized Controlled Trial

validated questionnaire describing individual nausea

Alex Farr, MD PhD

Assistant Professor, Consultant Physician

Medical University of Vienna

Hyperalgesia

Pain, Postoperative

Andrea Fanelli

DNA Methylation and Perioperative Pain Treatment

Explorative Study About the Degree of DNA Methylation Related to Acute Perioperative Pain Treatment

University of Bologna

The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.

The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks.

Iron Deficiency Anemia

Ferrous bis-glycinate

Ferrous glycine sulphate

Assiut university

The Effect of Iron Deficiency Anemia During Pregnancy

Ferrous Bis-glycinate Versus Ferrous Glycine Sulfate for the Treatment of Iron Deficiency Anemia During Pregnancy

difference in hemoglobin concentrations before and after treatment

Ahmed Mohamed Abbas

Assiut University

ferrous bisglycinate chelate 1 tablet daily

ferrous bisglycinate chelate 2 tablets daily

Participants received ferrous bisglycinate chelate, 1 tablet of 60 mg, once-daily after dinner, via oral route for 8 weeks.

Ferrous Bisglycinate Chelate 60 mg 1 Once-daily

Participants received ferrous bisglycinate chelate, 1 tablet each of 60 mg, twice-daily after breakfast and dinner, via oral route for 8 weeks.

Ferrous Bisglycinate Chelate 60 mg 1 Twice-daily

Participants received ferrous ascorbate, 1 tablet of 100 mg once-daily after dinner, via oral route for 8 weeks.

Ferrous Ascorbate 100 mg 1 Once-daily

Total

Sex: Female, Male

Region of Enrollment

At fortnightly visits, blood was collected for Hb. Baseline (Visit 0) was not more than 5 days from Week 1 or randomization. Change from Baseline was calculated by subtracting Baseline values from post-Baseline values.

Change From Baseline in Hemoglobin (Hb) After 8 Weeks of Treatment in Each Ferrous Bisglycinate Chelate Group (1 Tablet Daily and 2 Tablets Daily)

Mean Change in Hb From Baseline to 8 Weeks

At fortnightly visits, blood was collected for Hb. Number of participants who achieved a target Hb of more than or equal to 12 gm/dL is presented.

Percentage of Participants Who Achieved a Target Hb More Than or Equal to 12 gm/dL After 8 Weeks of Treatment

At fortnightly visits, blood was collected for Hb. Mean change in Hb at Week 2, Week 4, Week 6 and Week 8 are presented.

Mean Change in Hb During 8 Weeks Therapy

The comparison in percentage of participants with gastrointestinal side effects during 8 week treatment period is reported. Gastrointestinal side effects during 8 weeks treatment included abdominal discomfort, gastritis, nausea, dyspepsia, change in bowel habit, constipation, faeces discolored, diarrhea and flatulence.

Difference in Percentage of Participants With Gastrointestinal Side Effects During 8 Weeks Treatment With Ferrous Bisglycinate Chelate and Ferrous Ascorbate

Overall Study

GSK Response Center

Haematopoiesis

ferrous ascorbate

ferrous bisglycinate chelate 1 OD

ferrous bisglycinate chelate 2 OD

GSK Investigational Site

A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.

A Multicentre, Randomized, Laboratory-blinded, Parallel-group Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.

ascorbate/opkast

Chewing Gum Containing Vitamin-c to Treat Emesis Gravidarum

DNA Methylation and Perioperative Pain Treatment

The Effect of Iron Deficiency Anemia During Pregnancy

A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.

High-Dose N-Acetylcysteine in Cardiac Surgery

Den mest komplette database med medicinske urter understøttet af videnskab